COMMUNIQUÉS West-GlobeNewswire

RavenQuest Signs MOU to Acquire Western AgriPharma Limited

03/04/2018 - 10:00

Vancouver, British Columbia, April 03, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE:RQB)(OTCQB:RVVQF)(Frankfurt: 1IT ) is pleased to announce that it has signed a Memorandum of [...]

Status update of the Phase III ARAMIS clinical trial with darolutamide in patients with non-metastatic castration-resistant prostate cancer

03/04/2018 - 09:31

ORION CORPORATION PRESS RELEASE 3 APRIL 2018 at 10.30 EEST Status update of the Phase III ARAMIS clinical trial with darolutamide in patients with non-metastatic castration-resistant prostate cancer Orion announced [...]

BioPorto receives intention to grant for a divisional NGAL cutoff patent in Europe

03/04/2018 - 09:25

April 3, 2018 Announcement no. 7 BioPorto receives intention to grant for a divisional NGAL cutoff patent in Europe The European Patent Office has published intention to grant BioPorto’s patent no. EP3208616. The patent [...]

Solon Eiendom ASA : Sales in Q1 2018

03/04/2018 - 08:31

Oslo, April 3, 2018 - Solon Eiendom sold 124 homes with a total sales value of NOK 819 million during the first quarter of 2018 compared to 58 homes with a total sales value of NOK 407 million in the first quarter of [...]

Publication of Biohit Oyj Annual Report 2017

03/04/2018 - 08:30

Biohit Oyj Annual Financial Report April 3, 2018 at 9:30 am local time (EET) Biohit Oyj’s Annual Report 2017 is published today in PDF format. The annual report contains financial statements for 2017, the Report of the [...]

Immunicum AB (publ) Provides Update on Ilixadencel Clinical Development Program

03/04/2018 - 08:01

Press Release 3 April 2018 Immunicum AB (publ) Provides Update on Ilixadencel Clinical Development Program Immunicum AB (publ; IMMU.ST) provided today an update on planned, ongoing and previously completed clinical [...]

Shire plc : Rule 2.9 Announcement

03/04/2018 - 08:01

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 3 April 2018 Shire [...]

genedrive to premier its Genedrive® Hepatitis C test in Asia Pacific

03/04/2018 - 08:00

3 April 2018 genedrive plc ("genedrive" or the "Company") Genedrive® HCV ID Kit to be presented at MEDLAB Asia Pacific Exhibition & Congress genedrive plc (AIM: GDR), the near patient molecular diagnostics company, [...]

Motif Bio Initiates NDA Rolling Submission for Iclaprim and Provides Business Update

03/04/2018 - 08:00

NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ: MTFB ), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the initiation of a rolling [...]

DBV Technologies to Attend the 11th Kempen Life Sciences Conference

03/04/2018 - 07:31

Montrouge, April 3, 2018 DBV Technologies to Attend the 11 th Kempen Life Sciences Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that Susanna Mesa, Chief [...]

DBV Technologies invitée à participer à la 11ème Life Sciences Conference de Kempen

03/04/2018 - 07:31

Montrouge, France, le 3 avril, 2018 (7H30 CEST) DBV Technologies invitée à participer à la 11ème Life Sciences Conference de Kempen DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq : DBVT), une société [...]

Sanofi: EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma

03/04/2018 - 07:01

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma Paris and Tarrytown, NY - April 3, 2018 - The European Medicines [...]

Sanofi : L'EMA va examiner le cemiplimab comme traitement potentiel du carcinome épidermoïde cutané au stade avancé

03/04/2018 - 07:01

Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) L'EMA va examiner le cemiplimab comme traitement potentiel du carcinome épidermoïde cutané au stade avancé Paris et Tarrytown (New York) - Le 3 avril [...]

Sanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma

03/04/2018 - 07:01

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) EMA to review Dupixent ® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma Paris and Tarrytown, NY - April 3, 2018 - The [...]

Sanofi : L'EMA va examiner Dupixent® (dupilumab) dans le traitement potentiel de l'asthme modéré à sévère inadéquatement contrôlé

03/04/2018 - 07:01

Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) L'EMA va examiner Dupixent® (dupilumab) dans le traitement potentiel de l'asthme modéré à sévère inadéquatement contrôlé Paris et Tarrytown (New York [...]

Fagron strengthens strategic position in USA through highly complementary acquisition of Humco

03/04/2018 - 07:01

Nazareth (Belgium)/Rotterdam (The Netherlands) 1 , 3 April 2018 Regulated information - Inside information Fagron strengthens strategic position in USA through highly complementary acquisition of Humco Fagron announces [...]

argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting

03/04/2018 - 07:01

Company to host workshop and webcast on April 24, 2018 at 1:00 p.m. PT April 3, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a [...]

Probiodrug reports full year 2017 financial results

03/04/2018 - 07:01

Probiodrug reports full year 2017 financial results PQ912 delivers positive pharmacodynamic and efficacy results in a Phase 2a study in early stage AD patients - data presented at CTAD, Boston, November 2017 PQ912 Phase [...]

Veloxis Appoints Morten Marott as Chief Financial Officer

03/04/2018 - 05:13

Company Release no. 08/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 03 April 2018 Veloxis Appoints Morten Marott as Chief Financial Officer Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that Morten [...]